This six-part series was written in collaboration with Kirsten Angeles and input from James Smith. You should find it particularly useful if you don't know much about drug development yet and want to get a comprehensive overview.

Knowledge about drug development is often fragmented, expensive, and jargon-heavy. With this series we don’t want to debate the pros and cons of the system’s overall value; we want to explain how it works and how it came to work like this. The articles below aim to provide a comprehensive but concise introduction to all pharma’s essential stakeholders, processes, and principles, connecting them to actionable insights and further resources:
 

1. Stakeholders in Drug Development
2. The Blueprint of Drug Development
3. Origins of Drug Regulation
4. Recommended Literature and Courses
5. Alvea: A Case Study of the Fastest Biotech to Go to In-Human Trials
6. Conclusions

Total read time is 45-60min.